| 000 | 01010 a2200313 4500 | ||
|---|---|---|---|
| 005 | 20250514214242.0 | ||
| 264 | 0 | _c20050429 | |
| 008 | 200504s 0 0 eng d | ||
| 022 | _a1462-3846 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGale, Christopher | |
| 245 | 0 | 0 |
_aGeneralised anxiety disorder. _h[electronic resource] |
| 260 |
_bClinical evidence _cJun 2004 |
||
| 300 |
_a1302-18 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAnti-Anxiety Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aAntidepressive Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aAnxiety Disorders _xdrug therapy |
| 650 | 0 | 4 |
_aBenzodiazepines _xtherapeutic use |
| 650 | 0 | 4 |
_aBuspirone _xtherapeutic use |
| 650 | 0 | 4 |
_aCarbolines _xtherapeutic use |
| 650 | 0 | 4 | _aCognitive Behavioral Therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHydroxyzine _xtherapeutic use |
| 650 | 0 | 4 | _aKava |
| 650 | 0 | 4 | _aPhytotherapy |
| 700 | 1 | _aOakley-Browne, Mark | |
| 773 | 0 |
_tClinical evidence _gno. 11 _gp. 1302-18 |
|
| 999 |
_c15331355 _d15331355 |
||